Health Care • Biotechnology: Electromedical & Electrotherapeutic Apparatus
$0.74 ▼ -0.04
(-5.23%)
MKT CAP: $78.9M • VOL: 680.4K
52W L $1 52W H $2
ROARABLE / RQD
D • 45/100
PIOTROSKI
6 / 9
HYPR // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $13.6M | $12.9M | $11.0M |
| YoY Revenue Growth % | +5.2% | +16.8% | — |
| Gross Profit | $6.8M | $5.9M | — |
| Gross Margin % | 49.8% | 45.7% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$37.1M | -$43.2M | -$48.1M |
| Operating Margin % | -80.0% | -80.0% | -80.0% |
| Net Income (GAAP) | -$35.6M | -$40.7M | -$44.2M |
| EBITDA (Normalized) | -$36.1M | -$42.9M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$27.9M | -$38.8M | -$41.8M |
| Capital Expenditures (CapEx) | $1.2M | $383.0K | — |
| Free Cash Flow (FCF) | -$29.1M | -$39.1M | -$41.8M |
| FCF Margin % | -80.0% | -80.0% | -80.0% |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $35.1M | $37.6M | — |
| Total Debt (Short + Long Term) | $0 | — | — |
| Total Stockholders' Equity | $41.0M | $49.0M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR HYPR.